Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Morphosys Ag (OP: MPSYF ) 73.27 UNCHANGED Last Price Updated: 3:33 PM EDT, Jul 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Morphosys Ag Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting August 27, 2024 Via ACCESSWIRE MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting April 24, 2024 Via ACCESSWIRE MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis April 11, 2024 Via ACCESSWIRE MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act March 21, 2024 Via ACCESSWIRE Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024 March 07, 2024 Via ACCESSWIRE Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023 November 09, 2023 Via ACCESSWIRE Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023 March 09, 2023 Via ACCESSWIRE MorphoSys AG: Financial Calendar 2023 November 28, 2022 Via ACCESSWIRE MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease November 14, 2022 Via ACCESSWIRE MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 07, 2024 Via ACCESSWIRE Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction November 20, 2023 Via ACCESSWIRE MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting November 02, 2023 Via ACCESSWIRE MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023 October 25, 2023 Via ACCESSWIRE MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer September 12, 2023 Via ACCESSWIRE MorphoSys Stops Work and Operations on Pre-Clinical Research Programs March 02, 2023 Via ACCESSWIRE Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022 November 10, 2022 Via ACCESSWIRE MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 October 21, 2022 Via ACCESSWIRE Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters March 02, 2023 Via ACCESSWIRE MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 January 09, 2023 Via ACCESSWIRE MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability January 05, 2023 Via ACCESSWIRE MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting November 03, 2022 Via ACCESSWIRE MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors October 27, 2022 Via ACCESSWIRE MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022 July 28, 2022 Via ACCESSWIRE MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 July 26, 2022 Via ACCESSWIRE GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis October 27, 2022 Via ACCESSWIRE MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022 July 28, 2022 Conference Call Alert From MorphoSys AG Via AccessWire MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 July 26, 2022 PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary U.S. net product sales of Monjuvi® (tafasitamab-cxix) for the second quarter 2022... From MorphoSys AG Via AccessWire MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 July 26, 2022 Via ACCESSWIRE MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 July 26, 2022 Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 From MorphoSys AG Via AccessWire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
